natgillin/translations-raw huggingface dataset:
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds. 
mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 109/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi.
If you take more Clopidogrel HCS than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. 
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions'). 
• znaki jetrnih težav, npr. porumenelost kože in/ali oči (zlatenica), ki so lahko povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2
What Clopidogrel HCS looks like and contents of the pack 
Izgled zdravila Klopidogrel HCS in vsebina pakiranja
If you forget to take Clopidogrel HCS 
Če ste pozabili vzeti zdravilo Klopidogrel HCS
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
Tako kot druge antitrombotike tudi klopidogrel previdno uporabljamo pri bolnikih, pri katerih zaradi poškodbe, kirurškega posega ali drugih patoloških stanj obstaja tveganje za povečano krvavitev, in pri bolnikih, ki so na zdravljenju z ASA, s heparinom, z zaviralci glikoproteina IIb/IIIa ali z nesteroidnimi protivnetnimi zdravili (NSAID), vključno z zaviralci ciklooksigenaze-2 (COX-2) ali s selektivnimi zaviralci privzema serotonina (SSRI) ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve,
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking 
Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika,
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with 
(toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), akutna generalizirana eksantemska pustuloza (AGEP), angioedem, z zdravili povzročen sindrom preobčutljivosti
If you stop taking Clopidogrel HCS 
Če ste prenehali jemati zdravilo Klopidogrel HCS
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD). 
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen (PAD) Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
What you need to know before you take Plavix Do not take Plavix: 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel HCS Ne jemljite zdravila Klopidogrel HCS:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
EU/1/10/651/001 28 film-coated tablets EU/1/10/651/002 30 film-coated tablets EU/1/10/651/003 50 film-coated tablets EU/1/10/651/004 56 film-coated tablets EU/1/10/651/005 84 film-coated tablets EU/1/10/651/006 90 film-coated tablets EU/1/10/651/007 100 film-coated tablets EU/1/10/651/008 28x1 film-coated tablets EU/1/10/651/009 28x1 film-coated tablets (calendar pack) EU/1/10/651/010 30x1 film-coated tablets EU/1/10/651/011 50x1 film-coated tablets EU/1/10/651/012 56x1 film-coated tablets EU/1/10/651/013 84x1 film-coated tablets EU/1/10/651/014 90x1 film-coated tablets EU/1/10/651/015 100x1 film-coated tablets 
EU/1/10/651/001 28 filmsko obloženih tablet EU/1/10/651/002 30 filmsko obloženih tablet EU/1/10/651/003 50 filmsko obloženih tablet EU/1/10/651/004 56 filmsko obloženih tablet EU/1/10/651/005 84 filmsko obloženih tablet EU/1/10/651/006 90 filmsko obloženih tablet EU/1/10/651/007 100 filmsko obloženih tablet EU/1/10/651/008 28x1 filmsko obloženih tablet EU/1/10/651/009 28x1 filmsko obloženih tablet (koledarsko pakiranje) EU/1/10/651/010 30x1 filmsko obloženih tablet EU/1/10/651/011 50x1 filmsko obloženih tablet EU/1/10/651/012 56x1 filmsko obloženih tablet EU/1/10/651/013 84x1 filmsko obloženih tablet EU/1/10/651/014 90x1 filmsko obloženih tablet EU/1/10/651/015 100x1 filmsko obloženih tablet
For the 28x1 tablets pack size, you can check the day on which you last took a tablet of Clopidogrel HCS by referring to the calendar printed on the blister. 
Če uporabljate pakiranje 28 x 1 tableta, lahko dan, ko ste nazadnje vzeli tabletozdravila Klopidogrel
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). 
Koristi, ki so jih opazili s klopidogrelom, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa,
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
pri britju, navadno ni razloga za skrb, če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4»Možni neželeni učinki«);
Paediatric population 
• Pediatrična uporaba
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. 
Pri odraslih bolnikih z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke in ki niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo majhno tveganje za krvavitev,
Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%). 
Hujše krvavitve so bile v obeh skupinah večinoma ekstrakranialne (5,3 % v skupini s klopidogrelom + ASA, 3,5 % v skupini s placebom + ASA),
While you are taking Clopidogrel HCS: 
Ko jemljete zdravilo Klopidogrel HCS:
Clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Klopidogrel previdno dajemo bolnikom, ki sočasnega jemljejo zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
(intention to treat analysis) so v skupini, ki je jemala klopidogrel, opazili 939 dogodkov, v skupini, ki je jemala ASA, pa 1.020 dogodkov (zmanjšanje relativnega tveganja /RT/: 8,7%%, 95-odstotni interval zaupanja /IZ/: 0,2 do 16,4; p = 0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 (IZ: 0 do 20) bolnikom.
How to take Clopidogrel HCS 
Kako jemati zdravilo Klopidogrel HCS
OPA/Al/PVC-Al blisters containing 28, 30, 50, 56, 84, 90 and 100 film-coated tablets or perforated unit dose blister (OPA/Al/PVC-Al) containing 28x1, 28x1 (calendar pack), 30x1, 50x1, 56x1, 84x1, 90x1 and 100x1 film-coated tablets in a carton. 
OPA/Al/PVC-Al pretisni omoti , ki vsebujejo po 28, 30, 50, 56, 84, 90 in 100 filmsko obloženih tablet ali perforirani, enoodmerni pretisni omoti (OPA/Al/PVC-Al), ki vsebujejo po 28x1, 28x1 (koledarsko pakiranje), 30x1, 50x1, 56x1, 84x1, 90x1 in 100x1 filmsko obloženo tableto v škatli.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group. 
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5%) v skupini zdravljeni s klopidogrelom in 1.187 (18,8%) v skupini s placebom, to je 14% zmanjšanje relativnega tveganja (95% IZ od 6% -21%, p=0,0005) za skupino,
EU/1/10/651/001 Cartons of 28 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/002 Cartons of 30 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/003 Cartons of 50 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/004 Cartons of 56 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/005 Cartons of 84 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/006 Cartons of 90 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/007 Cartons of 100 film-coated tablets in OPA/Al/PVC - Al blisters EU/1/10/651/008 Cartons of 28x1 film-coated tablets in OPA/Al/PVC - Al perforated unit-dose blisters 
EU/1/10/651/001 škatla z 28 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/002 škatla s 30 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/003 škatla s 50 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/004 škatla s 56 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/005 škatla s 84 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/006 škatla z 90 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/007 škatla s 100 filmsko obloženimi tabletami v OPA/Al/PVC - Al pretisnih omotih EU/1/10/651/008 škatla z 28x1 filmsko obloženo tableto v OPA/Al/PVC - Al perforiranih enoodmernih pretisnih omotih
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). 
Peroralni antikoagulanti Sočasno jemanje klopidogrela in peroralnih antikoagulantov ni priporočljivo, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
Rash, pruritus, skin bleeding (purpura) 
kožne krvavitve (purpura)
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
(sindrom DIHS, Drug-Induced Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), eritematozni ali eksfoliativen izpuščaj, urtikarija, ekcem, lihen planus
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel HCS. 
Med jemanjem zdravila Klopidogrel HCS ne smete dojiti.
ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation. 
ASA ni spremenila s klopidogrelom dosežene inhibicije z ADP-jem sprožene agregacije trombocitov,
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose). 
Zaviralci protonske črpalke (PPI): Če sta bila klopidogrel in omeprazol uporabljena skupaj istočasno ali v presledku 12 ur, se je izpostavljenost aktivnemu presnovku klopidogrela zmanjšala za 45 % (začetni odmerek) oz. 40 % (vzdrževalni odmerek).
During non clinical studies in rat and baboon, the most frequently observed effects were liver changes. 
5.3 Predklinični podatki o varnosti V predkliničnih študijah na podganah in pavijanih so bile najpogosteje opaženi učinek jetrne spremembe.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala,
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da je sočasno jemanje fenitoina in tolbutamida, ki se presnavljata s
If you get any side effects, talk to your doctor or pharmacist. 
Če opazite kateri koli neželeni učinek , se posvetujte z zdravnikom ali farmacevtom.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
V študiji CAPRIE so primerjali klopidogrel in ASA, v študijah CURE, CLARITY, COMMIT in ACTIVE_A pa klopidogrel in placebo; bolniki so oboje dobivali v kombinaciji z ASA in drugo standardno terapijo.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder 
Izdelovalec: KRKA, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija
- swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
• otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži kar so lahko znaki alergijske reakcije.
Posology • Adults and elderly 
• Odrasli in starejši (več kot 65 let)
Patients were treated for up to 5 years. 
bolnikov v starosti ≥ 65 let.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (28x1 film-coated tablets-calendar pack) 
PRETISNI OMOT (28x1 filmsko obložena tableta - koledarsko pakiranje) IME ZDRAVILA
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia 
4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin, or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, 
o nesteroidna protivnetna zdravila, običajno za lajšanje bolečih in/ali vnetih sklepov ali mišic, o heparin ali katero koli drugo zdravilo za preprečevanje strjevanja krvi, o tiklopidin, druga antiagregacijska zdravila, o selektivni zaviralci privzema serotonina (na primer fluoksetin ali fluvoksamin, a ne le tadva), ki se po navadi uporabljajo za zdravljenje depresije, - omeprazol ali esomeprazol, zdravila za zdravljenje težav z želodcem,
Glomerulonephritis, blood creatinine increased 
Bolezni sečil hematurija glomerulonefritis,
Hypromellose (E464) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171) Red iron oxide (E172) 
Filmska obloga: polivinilalkohol titanov dioksid (E171)
Clopidogrel HCS 75 mg film-coated tablets clopidogrel 
Klopidogrel HCS 75 mg filmsko obložene tablete klopidogrel
Clopidogrel HCS 75 mg film-coated tablets 
Klopidogrel HCS 75 mg filmsko obložene tablete
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Vendar pa so bolniki, ki so bili vključeni v klinično preizkušanje klopidogrela, brez dokazov o klinično pomembnih neželenih interakcijah sočasno jemali različna zdravila, tudi diuretike, zaviralce adrenergičnih receptorjev beta, zaviralce angiotenzinske konvertaze (ACE), kalcijeve antagoniste, učinkovine za zniževanje holesterola,
− Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
- če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času;
The number of patients who reached the primary endpoint (time to first occurrence of stroke, MI, non-CNS systemic embolism or vascular death) was 832 (22.1%) in the group treated with clopidogrel + ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes. 
bolnikov in v skupini s placebom + ASA 924 (24,4 %) bolnikov (relativno zmanjšanje tveganja 11,1 %, 95 % IZ: od 2,4 % do 19,1 %, p = 0,013), predvsem kot posledica velikega zmanjšanja incidence možganskih kapi.
Plavix contains lactose 
Okvara ledvic
Plavix is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Proces je znan kot aterotromboza in lahko povzroči aterotrombotične dogodke (kot so kap, srčni napad ali smrt).
SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution. 
Selektivni zaviralci privzema serotonina (SSRI; Selective serotonin re-uptake inhibitors) Selektivni zaviralci privzema serotonina vplivajo na aktivacijo trombocitov in povečajo nevarnost krvavitve, zato je ob sočasnem jemanju selektivnih zaviralcev privzema serotonina in klopidogrela potrebna previdnost.
• Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil. 
• Pomožne snovi so (glejte poglavj 2 »Zdravilo Klopidogrel HSC vsebuje hidrogenirano ricinusovo olje«) : - Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000, hidrogenirano ricinusovo olje
Polyvinyl alcohol Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc 
rumeni železov oksid (E172)
If you take more Plavix than you should 
Če ste vzeli večji odmerek zdravila Klopidogrel HCS, kot bi smeli
- a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body). 
- zdravstveno stanje s tveganjem za notranjo krvavitev (rana na želodcu), - krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa), - nedavna huda poškodba, - nedavni kirurški poseg (tudi na zobeh),
EU/1/10/651/013 Cartons of 84x1 film-coated tablets in OPA/Al/PVC - Al perforated unit-dose blisters 
EU/1/10/651/013 škatla s 84x1 filmsko obloženo tableto v OPA/Al/PVC - Al perforiranih enoodmernih pretisnih omotih
Thu 
VKA.
EU/1/10/651/012 Cartons of 56x1 film-coated tablets in OPA/Al/PVC - Al perforated unit-dose blisters 
EU/1/10/651/012 šklatla s 56x1 filmsko obloženo tableto v OPA/Al/PVC - Al perforiranih enoodmernih pretisnih omotih
EU/1/10/651/011 Cartons of 50x1 film-coated tablets in OPA/Al/PVC - Al perforated unit-dose blisters 
EU/1/10/651/011 škatla s 50x1 filmsko obloženo tableto v OPA/Al/PVC - Al perforiranih enoodmernih pretisnih omotih
These may be due to rare decrease of some blood cells. 
• zvišana telesna temperatura, znaki okužbe ali huda utrujenost, kar so znaki redkega zmanjšanja števila določenih krvnih celic;
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel HCS per day to be taken orally with or without food, and at the same time each day. 
(nepravilen srčni utrip), je ena 75 mg tableta zdravila Klopidogrel HCS na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
(listed in section 6). 
ali v poglavju 6.1.
Clopidogrel HCS is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Zdravilo Klopidogrel HCS jemljejo odrasli za preprečevanje nastanka krvnih strdkov (trombov) v otrdelih krvnih žilah (arterijah).
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4. 
Aktivni presnovek nastane predvsem z delovanjem CYP2C19, k nastanku pa pripomorejo tudi drugi encimi
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease 
- ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen ali
How to store Clopidogrel HCS 
Shranjevanje zdravila Klopidogrel HCS
The most common side effect reported with Clopidogrel HCS is bleeding. 
Najpogostejši neželeni učinek, o katerem so poročali med zdravljenjem z zdravilom Klopidogrel
Vistor hf. 
Klopidogrel HCS, ne dojijo.
Nervous system 
Organski sistem Pogosti
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja modrice izpuščaj, srbenje,
Medicinal products associated with bleeding risk: 
• če pri vas obstaja tveganje za krvavitev, kot je:
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Navodilo za uporabo Klopidogrel HCS 75 mg filmsko obložene tablete klopidogrel Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. 
Pri manjših urezninah ali poškodbah, npr.
Always take this medicine exactly as your doctor or pharmacist has told you. 
Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika ali faramecvta.